

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number  
**WO 01/41550 A2**

(51) International Patent Classification: Not classified

(21) International Application Number: PCT/US00/41451

(22) International Filing Date: 23 October 2000 (23.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/161,155 22 October 1999 (22.10.1999) US

(71) Applicant (for all designated States except US): COM-  
POUNDINGPHARMACIES.COM, INC. [US/US]; 325  
Queens City Avenue, Tuscaloosa, AL 35401 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): WEPFER, Scott  
[US/US]; 3209 Heathrow Downs, Hoover, AL 39226  
(US).

(74) Agents: COGEN, Ellen, S. et al.; Gifford, Krass, Groh,  
Sprinkle, Anderson & Citkowski, P.C., Suite 400, 280 N  
Old Woodward Avenue, Birmingham, MI 48009 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished  
upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 01/41550 A2

(54) Title: TOPICAL ANESTHETIC FORMULATION

(57) Abstract: The topical anesthetic formulation of the present invention is typically a solution that preferably includes lidocaine, USP as the active anesthetic ingredient with benzyl alcohol and isopropyl alcohol. This invention deals with problems commonly associated with topical application of local anesthetics such as: slow onset of action; need for occlusion; messiness of creams, ointments or gels; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the anesthetic and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.

## **TOPICAL ANESTHETIC FORMULATION**

### **Field of the Invention**

The present invention generally relates to topical anesthetics. More particularly, the present invention relates to a fast acting topical anesthetic or  
5 transdermal pain formulation for deep dermis anesthesia for use prior to and/or during medical procedures.

### **Background of the Invention**

The use of topical or dermal anesthetics has long been utilized in the practice of medicine. Topical anesthetics are commonly administered prior to  
10 procedures such as injections, biopsies, the application of laser energy for cutaneous procedures such as removal of hair, tattoos, telengectasias, etc., minor superficial surgeries, and the like.

One particular topical anesthetic utilized to suppress or eliminate pain during such procedures is known by the trade name EMLA®. This product is  
15 known to be effective as a topical anesthetic; however, EMLA® has a very long onset time, which is the time between administration of the topical anesthetic and the commencement of the anesthetic effect. It must also be covered with an occlusive dressing to enhance penetration. The onset time for EMLA® can range from 45 to 90 minutes and, in some instances, can take  
20 even longer. The variability in length of onset time leads to delays in the commencement of medical procedures and, because of the very wide variation in onset time, can lead to the premature commencement of procedures, thereby inflicting unnecessary pain on the patient.

Several topical anesthetic formulations have been extensively used by the medical field to obtain local anesthesia. These products are known to be effective as topical anesthetics; however, they typically have long onset times, which is the time between the administration of the topical anesthetic and the commencement of the anesthetic effect. They must also be covered with an occlusive dressing to enhance penetration. Also, the onset of action for these available topical anesthetics varies over a range of time, for example from 45 to 90 minutes. This variability in length of onset time leads to delays in the commencement of medical procedures and, because of the very wide variation in onset time, can lead to the premature commencement of procedures, thereby inflicting unnecessary pain on the patient. These current methods have used more viscous semi-liquid carriers such as creams, ointments or gels which can be quite messy to work with, which adds another inconvenience to the user. For example, they must be cleaned off the injection site before injecting.

Accordingly, it would be advantageous and desirable to develop a topical anesthetic formulation which has a shorter onset time, which has less variability in the onset time, does not require occlusion, is easier to apply with less mess and which is amenable to use for cutaneous laser procedures such as hair removal and skin resurfacing, as well as for use before giving injections, starting IVs, drawing blood, biopsies and minor superficial surgeries. Such a formulation will have a potent clinical use with a more rapid onset of action.

The ideal vehicle for such a formulation would enhance the percutaneous penetration of the active ingredient, allowing for a fast onset of

action. At the same time, the active ingredient must not penetrate so effectively through the skin as to be rapidly lost to the systemic circulatory systems. Thus, the ideal vehicle would also enhance the skin's ability to retain the pharmacologically active ingredient or, in other words, to increase skin residence times.

#### **Brief Summary of the Invention**

The present invention concerns a topical anesthetic formulation for topical administration to the surface of the skin and into the deeper regions of the dermis. The topical anesthetic formulation of the present invention is typically a solution that preferably includes lidocaine, USP as the active anesthetic ingredient. Additional constituents illustratively include benzyl alcohol and isopropyl alcohol.

The invention confronts the paradoxical requirement that a local anesthetic quickly penetrate into the skin and produce a rapid onset of action, yet not penetrate the skin until it reaches into the systemic circulation. The anesthetic does not have an adversely prolonged effect.

The present invention permits enhanced penetration of the anesthetic and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.

20

#### **Detailed Description of the Invention**

The present invention provides a topical anesthetic formulation for topical administration to the surface of the skin and into the deeper regions of the dermis. The topical anesthetic formulation of the present invention is

typically a solution which includes lidocaine, USP; benzyl alcohol, NF, anhydrous; isopropyl alcohol and USP.

Lidocaine, USP is the preferred active anesthetic ingredient. Advantages include its time to onset of action which is 0.5 to 1 minute.

5 Another advantage of lidocaine is that methemoglobinemia is not a concern as it is in formulations which contain prilocaine.

The base or unionized form of this drug was intentionally chosen because it is significantly more soluble in benzyl alcohol and also because studies show that bases of local anesthetics more easily traverse the stratum  
10 corneum than do their salts. Lipid solubility appears to not only be the primary determinant of intrinsic anesthetic potency, the onset of action is also directly related to the percent of drug that exists in the base form since it is unchanged for that is primarily responsible for diffusion across the nerve sheath.

The key to this non-aqueous solvent and transdermal penetration  
15 system is benzyl alcohol. Benzyl alcohol has demonstrated its ability to not only solvate lipophilic (non-ionic) compounds, but to form a micelle, a property conducive to penetration of the stratum corneum. The high lipid solubility of lidocaine base as well as that of the benzyl alcohol greatly diminishes the need for a vasoconstrictor to be added to the formula to prolong  
20 the duration of anesthesia. Thus, the lipophilic nature is seen as a positive quality since vasoconstrictors are also contraindicated for many of the procedures for which this system will benefit, such as starting an IV and laser

removal of telangiectasias. In both of these instances, vasoconstriction decreases the chances for success of the medical procedure.

The amphoteric properties of benzyl alcohol - its strong lipophilicity and moderate hydrophilicity - allow it to disrupt the highly structured lipid portion of the stratum corneum, or fluidizing its lipids, thus allowing lipid soluble drugs to pass through the stratum corneum at increased rates of absorption. It is then the same strong lipophilicity which enhances penetration that also significantly enhances the retention of lipophilic drugs in the subcutaneous tissues underlying the site of application, thus increasing the duration of local action and decreasing systemic side-effects by slowing continued penetration into the systemic circulation. Thus, more anesthetic molecules are allowed to reach the nerve membrane which improves the depth and duration of anesthesia.

Besides being an anesthetic itself, its ability to fluidize membranes may also play a role in the system's ability to bring about such a markedly fast onset of action.

The isopropyl alcohol is used as a co-solvent. Once applied to the skin, this co-solvent rapidly evaporates from the skin due to its greater volatility. As this happens, the drug is transferred to the less volatile phase, benzyl alcohol, which, due to its very rapid permeation and good solvent characteristics, prevents the deposition of solutes on the skin surface.

It is appreciated that other topical anesthetic compounds are operative herein in place of the above active anesthetic. Alternative topical anesthetic

compounds illustratively include bupivacaine, chloroprocaine, oxyprocaine, mepivacaine, piperocaine, tetracaine, procaine, dibucaine, benzocaine, dyclaine and salts thereof. It is also contemplated that the present invention can optionally include a vasoconstrictor. Phenylephrine is a representative

5 vasoconstrictor which could be utilized to keep the active ingredients localized to the site to which they are applied. Other vasoconstrictors could include naphazole, tetrahydrozoline, oxymetazoline, tramazoline, and salts thereof. The addition salts of these compounds can be utilized in the formulation of the present invention. The benzyl alcohol serves as a penetration enhancer to

10 allow deeper layers of the dermis to be anesthetized. The isopropyl alcohol serves as a co-solvent.

Typical ranges of the present invention are provided in Table I.

**Table I. Typical Composition Ranges for Inventive Topical Anesthetic in Total Weight Percent of the Formulation**

Agent	Component	Typical Range Values	Preferred Range
Vasoconstrictor (total)		0.05-5	1-3
	phenylephrine HCl	0.05-5	1-3
Anesthetic (total)		1-25	5-16
	procaine HCl	0-15	0.5-4
	lidocaine HCl	0-20	0.5-6
	tetracaine HCl	0-25	1-9
Skin Penetration Enhancer (total)		0-35	5-21
	benzyl alcohol	0-35	1-10
	propylene glycol	0-35	3-14
VOC and base		40-99	70-90

15 It is appreciated that a variety of skin penetration enhancers, skin compatible and anesthetic solvating VOCs and bases in addition to those

detailed herein are known to one skilled in the art. Skin penetration enhancers additionally operative here in place of or in combination with those of Table I illustratively include ethoxydiglycol and those detailed in "Percutaneous Penetration Enhancers: The Fundamentals," E.W. Smith and H.I. Maibach, 5 July 1999, pp. 1-512, which is incorporated herein by reference. Additionally, a volatile organic compound intended to enhance evaporation such as isopropyl alcohol, an ether or halocarbon is optionally omitted in instances where rapid evaporation is not desired.

In use, a therapeutically effective amount of the topical anesthetic 10 formulation of the present invention is applied to the skin of a patient or subject prior to and/or during a medical procedure to treat the patient or subject.

The terms "patient" and "subject" mean all animals including humans. Examples of patients or subjects include humans, cows, dogs, cats, goats, sheep, and pigs.

15 The term "treating" includes, but is not limited to, the application of the topical anesthetic to the skin of a patient to prevent or inhibit the sensation of pain in the vicinity or region of the application of the topical anesthetic formulation.

20 A therapeutically effective amount is an amount of the topical anesthetic formulation of the present invention, that when administered to a patient or subject, ameliorates, eliminates and/or inhibits pain in the local region or vicinity of the application of the topical anesthetic of the present invention.



Dosage forms for topical administration of the formulation of the present invention include creams, gels, ointments and topical sprays. The active components are admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions, as well as dental formulations containing appropriate flavors and sweeteners, are also contemplated as being within the scope of this invention.

The topical anesthetic or transdermal pain formulation of the present invention can be packaged in a spray bottle or other suitable delivery device and can be applied to the surface of the skin utilizing a cotton swab, gauze pad, or other suitable applicator. A preferred formulation of the present invention can be made by combining the following ingredients:

To make 30 ml:

lidocaine, USP	1.2 gm	(active ingredient)
benzyl alcohol	3.0 ml	(penetration enhancer)
isopropyl alcohol	8.0 ml	(to aid in quick drying by evaporation)

Mixing instructions:

Weigh out first four ingredients.  
Transfer to 100 ml beaker.  
Add paraben-preserved water.  
Stir until dissolved.  
When dissolved, add benzyl alcohol, isopropyl alcohol and propylene glycol.  
Stir until well mixed.  
Dispose in sprayer bottle.

Applicants have found the formulation according to the present invention to be 100% effective in preventing any discomfort associated with the laser removal of hair using an Alexandrite Laser in twelve of twelve

patients. In six of these instances, the procedure had been previously done once before utilizing EMLA® gel which was applied approximately ninety minutes prior to the initiation of the laser hair removal. In these six patients, their procedures had to be stopped prematurely due to patient discomfort.

5 When the patients were re-lasered after pre-treating with the transdermal pain formulation of the present invention, none of these six patients reported any discomfort from the second procedure which was completed. One of the twelve patients or subjects was a male who had hair removed from his back. This is an interesting result because, of the different types of laser hair removal  
10 procedures, the removal of hair from the back is thought to be the most painful.

While the use of the transdermal pain formulation or topical anesthetic formulation of the present invention has been described for use in the laser removal of hair, Applicant contemplates other uses including use prior to laser skin resurfacing and other cutaneous laser procedures, use prior to injection or  
15 insertion of an intravenous needle such as for the initiation of an intravenous drip, use prior to other types of needle sticks such as IM injections, inoculations and blood drawing, or other suitable uses for topical or transdermal anesthesia which are well known to those skilled in the art.

In view of the teaching presented herein, other modifications and  
20 variations of the present invention will readily be apparent to those of skill in the art. The discussion and description are illustrative of some embodiments of the present invention, but are not meant to be limitations on the practice

thereof. It is the following claim, including all equivalents, which defines the scope of the invention.

Claims

- 1     1.     A formulation comprising at least one anesthetic compound selected  
2           from the group consisting of procaine, lidocaine, tetracaine and salts  
3           thereof; and skin penetration enhancer and volatile co-solvent in an  
4           anhydrous solution.
  
- 1     2.     The formulation of claim 1 wherein said skin penetration enhancer is at  
2           least one compound selected from the group consisting of: benzyl  
3           alcohol, propylene glycol, and ethoxydiglycol.
  
- 1     3.     The formulation of claim 1 wherein said vasoconstrictor is  
2           phenylephrine.
  
- 1     4.     The formulation of claim 1 further comprising a VOC.
  
- 1     5.     The formulation of claim 4 wherein the VOC is selected from the group  
2           consisting of isopropyl alcohol, ether and halocarbon.
  
- 1     6.     The formulation of claim 1 wherein said at least one anesthetic  
2           compound is present in said formulation from 1 to 25 total weight  
3           percent.

1        7.        The formulation of claim 6 wherein said at least two anesthetic  
2                    compounds are present in said formulation from 5 to 16 total weight  
3                    percent.

1        8.        The formulation of claim 1 wherein said at least two anesthetic  
2                    compounds are procaine, lidocaine and tetracaine, or salts thereof.

1        9.        The formulation of claim 8 wherein procaine is present from 0.5-4 total  
2                    weight percent, lidocaine is present from 0.5-6 total weight percent, and  
3                    tetracaine is present from 1-9 total weight percent.

1        10.       The formulation of claim 1 wherein said skin penetration enhancer is  
2                    present from 0 to 35 total weight percent.

1        11.       The formulation of claim 10 wherein said skin penetration enhancer is  
2                    present from 5 to 21 total weight percent.

1        12.       The formulation of claim 1 wherein said vasoconstrictor is present from  
2                    0.05 to 5 total weight percent.

1        13.       An aqueous formulation comprising:  
2                    at least two topical anesthetic compounds present from 5 to 16 total  
3                    weight percent;  
4                    a vasoconstrictor present from 1 to 3 total weight percent; and

5 a skin penetration enhancer present from 5 to 21 total weight percent.

1 14. A method for reducing pain associated with the application of laser  
2 energy to the skin, said method comprising the step of applying a  
3 therapeutically effective amount of a topical anesthetic according to  
4 claim 1 to the area of the skin to be treated prior to the application of  
5 laser energy.

1 15. The use of a formulation according to claim 1 as a topical anesthetic.

1 16. A commercial kit comprising at least one topical anesthetic compound  
2 formulated as an aqueous solution with a vasoconstrictor and a skin  
3 penetration enhancer together with instructions for use thereof as a  
4 topical anesthetic.

17. A transdermal anesthetic biphasic solvent system formula comprising:  
from 1 to 10 weight percent of a pharmaceutically active compound in  
base form;  
from about 5 to about 15 weight percent of benzyl alcohol; and  
from 50 to 95 weight percent of at least one co-solvent which possess  
greater volatility than the benzyl alcohol.

18. The system of claim 17 wherein said pharmaceutically active ingredient  
is lidocaine USP present at about 4 weight percent of the system.

19. The system of claim 17 wherein benzyl alcohol is present at about 10% weight percent of the system.
20. The system of claim 17 wherein said co-solvent is anhydrous isopropyl alcohol present at about 90% weight percent of the system.
21. The system of claim 17 further comprising a flavor or sweetener.
22. The system of claim 21 wherein from 50 to 95 weight percent of the formula is purified water as the co-solvent.
23. A method of local anesthesia comprising the step of applying to intact skin or oral mucosa the formula of claim 17.
24. The use of the formula of claim 17 as a topical anesthetic during a medical procedure.
25. The use of claim 24 wherein the medical procedure is selected from the group consisting of: injections, starting an IV, drawing blood, performing cutaneous laser procedures such as hair, tattoo, or port wine stain removal, biopsies, minor superficial surgeries, and the like.





(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number  
**WO 01/41550 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/24**,  
31/135

(21) International Application Number: PCT/US00/41451

(22) International Filing Date: 23 October 2000 (23.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/161,155 22 October 1999 (22.10.1999) US

(71) Applicant (for all designated States except US): **TRANSDERMATECH, INC.** [US/US]; 325 Queens City Avenue, Tuscaloosa, AL 35401 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **WEPFER, Scott** [US/US]; 3209 Heathrow Downs, Hoover, AL 39226 (US).

(74) Agents: **COGEN, Ellen, S.** et al.; Gifford, Krass, Groh, Sprinkle, Anderson & Citkowski, P.C., Suite 400, 280 N Old Woodward Avenue, Birmingham, MI 48009 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

-- with international search report

(88) Date of publication of the international search report:  
13 December 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/41550 A3**

(54) Title: TOPICAL ANESTHETIC FORMULATION

(57) Abstract: The topical anesthetic formulation of the present invention is typically a solution that preferably includes lidocaine, USP as the active anesthetic ingredient with benzyl alcohol and isopropyl alcohol. This invention deals with problems commonly associated with topical application of local anesthetics such as: slow onset of action; need for occlusion; messiness of creams, ointments or gels; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the anesthetic and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/41451

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/24, 31/135  
US CL : 514/535,653

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 514/535,653

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 3,832,460 <i>A</i> (KOSTI) 27 August 1974 (27.08.74), see the entire document.	1-25
A	US 4,808,410 <i>A</i> (SORRENTINO et al.) 28 February 1989 (28.02.89), see the entire document.	1-25
A	US 5,900,249 <i>A</i> (SMITH) 04 May 1999 (04.05.99), see the entire document.	1-25

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*B\* earlier application or patent published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\*

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\*

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\*

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\*

document member of the same patent family

Date of the actual completion of the international search

30 May 2001 (30.05.2001)

Date of mailing of the international search report

08 AUG 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Raymond J. Henley III

Telephone No. 703-308-1235

Form PCT/ISA/210 (second sheet) (July 1998)